Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems (VEEV) delivers cloud solutions transforming life sciences operations through CRM, quality management, and regulatory compliance tools. This news hub provides investors and industry professionals with essential updates on the company's strategic developments.
Access real-time announcements including quarterly earnings, product innovations, and strategic partnerships. Our curated collection features press releases about Veeva Vault implementations, AI-enhanced CRM capabilities, and compliance milestones critical for pharmaceutical and biotech organizations.
Bookmark this page for verified updates on clinical trial management advancements, quality control system upgrades, and regulatory submissions supported by Veeva's industry-specific platforms. Stay informed about developments impacting life sciences technology landscapes through our neutral, comprehensive reporting.
Veeva Systems (NYSE: VEEV) introduced enhancements to Veeva CRM at the European Veeva Commercial and Medical Summit on November 18, 2021. These updates cater to the evolving dynamics of healthcare professional (HCP) engagement by providing a simplified experience for in-person and digital channels. Key features include device flexibility, role-based applications, and tailored workflows, allowing field teams to operate efficiently across various devices. Veeva CRM is utilized by 42 of the top 50 pharmaceutical firms, underscoring its industry position.
Veeva Systems announced the launch of Veeva CRM Engage Connect at the European Veeva Commercial and Medical Summit on November 18, 2021. This new feature enhances compliant messaging and content sharing for healthcare professionals (HCPs) through the Veeva Engage app, used by over one million HCPs. Engage Connect enables direct communication between HCPs and life sciences companies, providing resources and scheduling options, facilitating a more personal interaction.
Available next month, this innovation aims to improve engagement and support patient care.
On Nov. 16, 2021, Veeva Systems (NYSE: VEEV) announced that the Center for Breakthrough Medicines (CBM) adopted the Veeva Vault Quality Suite to enhance development and manufacturing services for cell and gene therapies. The partnership aims to streamline quality processes and accelerate the delivery of therapies. CBM, a CDMO, focuses on increasing access to advanced therapies. The Veeva Vault Quality Suite will enable CBM to harmonize quality processes, boost efficiency, and improve collaboration across its manufacturing network, supporting its goal of establishing a leading therapy manufacturing facility.
Veeva Systems will announce its third fiscal quarter results for 2022 on December 1, 2021, after market close. The company will hold a conference call at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results. Prepared remarks will be available on its investor relations website approximately 55 minutes before the call. Veeva, a leader in cloud software for the life sciences sector, serves over 1,000 customers worldwide, including major pharmaceutical companies and emerging biotechs.
Veeva Systems (NYSE: VEEV) announced the adoption of its Vault Safety Suite by over 50 organizations, including a top global pharmaceutical company, simplifying case processing and pharmacovigilance management. The suite enhances collaboration and provides real-time safety management, benefiting sponsors and CROs with seamless adverse event processing. New features, such as a MedDRA multilingual browser and E2B import capabilities, have been added to improve efficiency. Veeva continues to commit to innovation and customer success in the life sciences industry.
Veeva Systems (NYSE: VEEV) announced that the adoption of its Veeva Vault CDMS by biotechs for oncology trials has more than doubled over the past year. The platform offers flexibility and speed, enabling data managers to make real-time study amendments without downtime, which is crucial for complex oncology studies. Over 40% of new studies awarded to Veeva in 2021 are oncology trials, benefiting from the ease of use and efficiency of Vault CDMS, which has been utilized in over 250 trials.
Veeva Systems has launched the TMF Bot, an AI-powered feature integrated into the Veeva Vault eTMF, designed to enhance trial management efficiency by automating document classification. Since its release, the TMF Bot has auto-classified over 40,000 documents across six customers, significantly reducing processing time. This innovation addresses challenges related to document misfiling and aims to streamline clinical trial processes, allowing study teams to focus on high-value activities while improving overall TMF accuracy and compliance.
Veeva Systems has launched the Veeva Digital Trials Platform, a technology ecosystem aimed at transforming clinical trial execution. This platform connects patients, research sites, and trial sponsors, enhancing data accuracy and diversity in trials. Key components include the Vault Clinical Suite, SiteVault Free, and MyVeeva for Patients. Early adopters, including major pharma companies, are already utilizing the platform to streamline operations and improve collaboration.
Veeva Systems (NYSE: VEEV) will hold a virtual Financial Analyst and Investor Day on October 28, 2021, from 9:00 a.m. PT to 11:00 a.m. PT. The event will be streamed live on the company's investor relations website, with an archived webcast available later. Registration for the event can be completed online. Veeva's commitment to the life sciences sector includes serving over 1,000 customers and prioritizing stakeholders' interests.
FAQ
What is the current stock price of Veeva Sys (VEEV)?
What is the market cap of Veeva Sys (VEEV)?
